EFPIA Highlights Europe ‘Lessons’ As Japan Ponders Policies
This article was originally published in PharmAsia News
EFPIA remains cautious over moves in Japan towards a formal health technology assessment system and possible changes to the reimbursement pricing system, calling again for the maintenance of an environment conducive to pharma innovation and pointing to lessons from its experience in Europe.
You may also be interested in...
Japan firms up proposals for expanded cost-effectiveness assessment scheme for selected drugs and devices after a policy committee outlines plans that could see associated price adjustments for reviewed products.
Amid intensifying official scrutiny of rising drug costs, the European industry federation EFPIA would like Japan to focus more on the measuring the actual benefits and health outcomes of new therapies, helped by new approaches and technology.
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.